This is a preview of subscription content, log in via an institution to check access.
Notes
National Health Service
see PharmacoEconomics & Outcomes News 838 p36; 803425772
Reference
NICE. Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine. Internet Document : 4 Feb 2020. Available from: URL: https://www.nice.org.uk/news/article/appeal-panel-rules-that-nice-needs-to-request-evidence-for-erenumab-effectiveness-in-subgroup-of-people-with-chronic-migraine
Rights and permissions
About this article
Cite this article
NICE requires further evidence on erenumab. PharmacoEcon Outcomes News 846, 37 (2020). https://doi.org/10.1007/s40274-020-6576-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6576-0